Inclusion Criteria:  Participants diagnosed with AD and confirmed from the medical record. At least 18 years of age living within the continental United States Patients treated with donepezil, the dose level must be stable for at least 3 months prior to screening. Read and understand English Have Internet and email access (this criterion applies to the legally authorized representatives) Agree to be contacted for future studies (during screening, participants are asked if they are interested in being contacted for future studies)  Exclusion Criteria:  Legally authorized representative unable or unwilling to provide informed consent No telephone access Treated with other medications used for AD (ex. memantine) or other cholinergic precursors (ex. choline alphoscerate, choline bitartrate, L-α-glycerophosphorylethanolamine) or other nootropics (ex. homotaurine) Epilepsy or head trauma resulting in unconsciousness in the past two years Presence of chronic obstructive pulmonary disease, asthma, severe cardiac insufficiency (congestive heart failure, myocardial infarction), type I diabetes, vitamin B12 or folic acid deficiency, liver cirrhosis, thyroid dysfunction, rheumatoid arthritis, chronic renal failure, and/or psychiatric disorders, obstructive sleep apnea, restless legs syndrome or periodic limb movement disorder; History of alcohol dependence and medication abuse Night shift workers or those in situations where they regularly experience jet lag, or have irregular work schedules, since circadian misalignment may alter markers of inflammation